Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 435 of 1259 results for pathway

  1. Midostaurin for treating advanced systemic mastocytosis (TA728)

    Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.

  2. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

  3. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

  4. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  5. Coban 2 for venous leg ulcers (MIB140)

    NICE has developed a medtech innovation briefing (MIB) on Coban 2 for venous leg ulcers .

  6. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

  7. Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery (TA170)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement in adults.

  8. Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

    Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.

  9. COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

    The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.

  10. Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)

    NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .

  11. Thora-3Di for assessing asthma in children (MIB122)

    NICE has developed a medtech innovation briefing (MIB) on Thora 3Di for assessing asthma in children .

  12. Archimedes for biopsy of suspected lung cancer (MIB211)

    NICE has developed a medtech innovation briefing (MIB) on Archimedes for biopsy of suspected lung cancer .

  13. Coexisting severe mental illness and substance misuse (QS188)

    This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.

  14. PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)

    NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .

  15. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.